Cynthia Forlini
Cynthia Forlini
Verified email at
Cited by
Cited by
The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?
W Hall, A Carter, C Forlini
The Lancet Psychiatry 2 (1), 105-110, 2015
Cognitive enhancement, lifestyle choice or misuse of prescription drugs?
E Racine, C Forlini
Neuroethics 3 (1), 1-4, 2010
Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of key stakeholders
C Forlini, E Racine
Neuroethics 2 (3), 163-177, 2009
Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement
C Forlini, E Racine
BMC Medical Ethics 10 (1), 1-13, 2009
Ethical issues raised by a ban on the sale of electronic nicotine devices
W Hall, C Gartner, C Forlini
Addiction 110 (7), 1061-1067, 2015
Stakeholder perspectives and reactions to “academic” cognitive enhancement: Unsuspected meaning of ambivalence and analogies
C Forlini, E Racine
Public understanding of science 21 (5), 606-625, 2012
Australian university students’ coping strategies and use of pharmaceutical stimulants as cognitive enhancers
C Jensen, C Forlini, B Partridge, W Hall
Frontiers in psychology 7, 277, 2016
Knowledge, experiences and views of German university students toward neuroenhancement: an empirical-ethical analysis
C Forlini, J Schildmann, P Roser, R Beranek, J Vollmann
Neuroethics 8 (2), 83-92, 2015
Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement
S Sattler, C Forlini, Racine, C Sauer
PLoS One 8 (8), e71452, 2013
Researchers’ perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey
K Riggall, C Forlini, A Carter, W Hall, M Weier, B Partridge, M Meinzer
Scientific reports 5 (1), 1-10, 2015
Expectations regarding cognitive enhancement create substantial challenges
E Racine, C Forlini
Journal of Medical Ethics 35 (8), 469-470, 2009
The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement
E Racine, TM Rubio, J Chandler, C Forlini, J Lucke
Medicine, Health Care and Philosophy 17 (3), 325-337, 2014
Navigating the enhancement landscape: Ethical issues in research on cognitive enhancers for healthy individuals
C Forlini, W Hall, B Maxwell, SM Outram, PB Reiner, D Repantis, ...
EMBO reports 14 (2), 123-128, 2013
Food addiction and its impact on weight-based stigma and the treatment of obese individuals in the US and Australia
NM Lee, WD Hall, J Lucke, C Forlini, A Carter
Nutrients 6 (11), 5312-5326, 2014
Added stakeholders, added value (s) to the cognitive enhancement debate: Are academic discourse and professional policies sidestepping values of stakeholders?
C Forlini, E Racine
AJOB Primary Research 3 (1), 33-47, 2012
Should physicians prescribe cognitive enhancers to healthy individuals?
C Forlini, S Gauthier, E Racine
CMAJ 185 (12), 1047-1050, 2013
Generating genius: how an Alzheimer’s drug became considered a ‘cognitive enhancer’for healthy individuals
L Wade, C Forlini, E Racine
BMC medical ethics 15 (1), 1-14, 2014
Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use
J Lucke, C Jensen, M Dunn, G Chan, C Forlini, S Kaye, B Partridge, ...
BMC public health 18 (1), 1-7, 2018
The is and ought of the ethics of neuroenhancement: mind the gap
C Forlini, W Hall
Frontiers in psychology 6, 1998, 2016
Brain disease model of addiction: misplaced priorities?
W Hall, A Carter, C Forlini
The Lancet Psychiatry 2 (10), 867, 2015
The system can't perform the operation now. Try again later.
Articles 1–20